Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh boy, one year ago I bought my first batch of warrants at 52c on 2/9/16 thinking this was the best BIO that I ever found. This is fuck up as of today. Sold all my warrants today (some before market closed lucky that I followed my 6th sense.) Life move on...good luck guys.
Why June?
Wrong...$200m/16m shares = $12.5
Late Jan is getting closer. NDA filing soon....hopefully this week.
News before CC next monday will be shock and awe!! ;)
I am hoping NDA/license deal news after market close on Friday, then the CC on Monday morning. ...
I agreed that they delayed one time. Originally it was suppose to be Q4/16. I expected they will file NDA later this month. Worse case is early Feb. But license deal or partnership news can can out anytime.
It went down last Friday because everyone disappointed that we are going to get a license deal instead of a BO this year.
There's no multiple delay. I don't know where you get that information. NDA will file in Q1/17.
Because the low share structure, a license deal for kit 302 will definitely turn out different comparing to PTN (250m shares). ; )
Total ads shares I guess we got around 17m now.
If I added right, ktov bought Tyrnovo for around $7m.
Ktov probably buy the other 44% by 21m shares = about 1m ads. Sounds like a cheap deal. Ktov is up on TASE is so far.
Need someone to translate Hebrew.
TASE news out: CEO Stock Exchange for listing securities from 1/16/17-private placement.
Buyout before May?
Tender Offer.
This Schedule 14D-9 relates to the tender offer by Plex Merger Sub, Inc., a Delaware corporation (“Purchaser”) and an indirect wholly owned subsidiary of Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland (“Parent”), to purchase all of the outstanding shares of Company Common Stock (“Shares”), at a purchase price of $30.25 per Share (the “Offer Price”), net to the Seller in cash, without interest (less any required withholding taxes), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 10, 2016 (as it may be amended or supplemented
"The TyrNovo acquisition represents a major milestone in Kitov's strategic vision of establishing a diverse pipeline that we believe will secure long term value creation for its shareholders. We are excited about NT219 and its prospects in the oncology field. NT219 can be developed as a platform combination drug for overcoming multi-drug resistance often observed in various tumors. It has the potential to be developed as a combination therapy with several approved oncology drugs for multiple types of tumors," stated Dr. Paul Waymack, Kitov's Chairman and Chief Medical Officer.
"The Kitov regulatory team has a proven track record in the development and approval of drugs for oncology as well as other indications required to develop NT219 towards submission of an IND and initiation of clinical trials," Waymack added.
Nice read.
http://www.wdrb.com/story/34247526/kitov-enters-immuno-oncology-field-through-acquisition-of-tyrnovo
The expansion into developing immuno-oncology drugs comes as Kitov plans to file its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its flagship combination drug, KIT-302, which is intended to treat osteoarthritis pain and hypertension simultaneously, in Q1 2017, with commercial launch anticipated for the first half of 2018. Kitov plans to harness its development and regulatory capabilities in proceeding towards submitting an investigational new drug (IND) application with the U.S. FDA and initiate clinical trials for its newly acquired drug, NT219.
The market for immuno-oncology treatments is believed to become worth $14 billion by 2019 and to grow to $34 billion by 2024, driven by long-term and durable tumor responses to immuno-oncology drugs, according to Global Data.
List of Patents:
Novel Protein Kinase Modulators and Therapeutic Uses Thereof
No. US8058309 Granted Nov 2011
Modulators of Protein Kinase Signaling
No. US8637575 Granted Jan 2014
Compounds Useful for the Treatment of Cancer
No. US20130274251 Granted Dec 2015
IGF-1R Signaling Pathway Inhibitors Useful in the Treatment of Neurodegenerative Diseases
No. 61/846014 PCT National Phase Jan 2016
Combinations of IRS/Stat3 Dual Modulators And Anti-Cancer Agents For Treating Cancer
No. PCT/IL2016/050134 Filed Feb 2016
Just a reminder.
"He was firm about the fact that this was NOT a delay. He said they had a few things that needed to be
completed beforehand, and that a December submission was going to be tough. He said it "may be
January, or perhaps February at the latest, but no further than that." They decided to say Q1/17 just to
be safe."
Let see how it goes. :)
5) Why was the NDA date pushed back from Q4/16 to as long as Q1/17 (Mar 31). What are we
waiting on, exactly?
He was firm about the fact that this was NOT a delay. He said they had a few things that needed to be
completed beforehand, and that a December submission was going to be tough. He said it "may be
January, or perhaps February at the latest, but no further than that." They decided to say Q1/17 just to
be safe.
I think most of us here are waiting for a BO of at least $300m and above. This is the most undervalue stock I ever found. That's why I am all in. :)
Well, I am betting big on this one. Hopefully we all get rich in 2017 AND RETIRE… Happy new year to all!! How many of you expected NDA will file around end of Jan besides me?
Waiting for KTOV to be like TBRA. :)
"Allergan plc (NYSE: AGN) and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that they have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion. The Boards of Directors of both companies have unanimously approved the transaction."
New 6k
Kitov Pharmaceuticals Holdings Ltd. (the “Company” or the “Registrant”) is announcing that on December 27, 2016, the Board of Directors of the Company (the “Board”) determined to fill a vacancy on the Audit Committee of the Board, and to appoint Mr. Ido Agmon, an independent director at the Company, to serve on the Audit Committee of the Board, effective immediately.
The present membership of the statutory committees of the Board is as follows:
? Audit Committee – Mr. Yair Katzir; Mr. Steven Steinberg; Mr. Ido Agmon
? Compensation Committee - Mr. Yair Katzir; Mr. Steven Steinberg; Mr. Ido Agmon
The Board has determined that all of the aforementioned directors meet the independence requirements and membership standards of the Exchange Act and NASDAQ Listing Rules for serving on the applicable committee.
Dang, I was tied up at work around closing time. Forgot about it.
Hmmm...it will be fun to slap 100 shares at 1.22 end of day to make my portfolio look good. ;)
Looks like tax selling on warrants are drying up. Smart ones already loaded up in last 2 weeks. Whoever wants a big chunk of it need to pay a higher price.
Nice, added 5k more today. Wouldn't add more unless if it goes down to 90s.
I will take out 5k at 1.15 soon
Are you serious? Russians did it?
Nice, I plan to add 5k more next week.
In July 2016, we completed a follow-on public offering of ADSs, non-listed Series B pre-funded warrants, and Series A warrants, for an aggregate of approximately $12,000,000. We believe our existing cash and cash equivalents will be sufficient to meet our anticipated cash requirements through at least the next twelve months.
Which one of you slapped 300 shares on me? Wasted my commission. :)
Changed bid to 10k. Let see who blink first. Lol
Got 5k at bid
But ktov's drug is better, unique with black label stated it's safer, most importantly we are patent protected until 2029.
Annual sales of Celebrex in the United States are reported at approximately $2.5 billion. Drug maker Pfizer is currently offering a co-pay card to eligible patients for branded Celebrex.
Celecoxib capsules may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction and strokes. It may also increase the risk of gastrointestinal bleeding, ulceration and perforation of the stomach or intestines.
I am at 90k warrants. Will add 10k more next week hopefully around 1.35 range.